PhenoTec AG offers a broad spectrum of preclinical services with an emphasis on acute and chronic lung diseases, infectious diseases, immunological and morphological investigations
Allergic asthma, Acute respiratory distress syndrome (ARDS), Subacute smoke exposure, bronchitis, Chronic bronchitis and fibrosis (CPOD), Lung emphysema
There is a dramatic rise of allergic asthma and a major need of novel, non-steroidal therapeutics for asthma. We have established severe allergic asthma models in mice with viral exacerbation to test novel therapies in mice.
Acute respiratory distress syndrome (ARDS)
ARDS is major respiratory emergency requiring effective therapy. We have established an endotoxin, ozone and virus induced models in mice. We have successfully tested novel therapies.
Subacute smoke exposure, bronchitis
CPOD is a major public health issue with chronic obstructive inflammation leading to respiratory insufficiency, for which there exist no effective treatment. Cigarette smoke exposure models in part CPOD, which we have established in mice (Doz E J Immunol 2008).
Chronic bronchitis and fibrosis (CPOD)
Another experimental approach is bleomycin induced bronchitis and lung fibrosis, a model which we also have fully established (Gasse et al J Clin Invest 2007). Mice are analysed at 1 and 14 days after bleomycin administration: BAL analysis, collagen, cytokines, and histology.
CPOD with the release of protease may also lead to destruction of alveolar septae known as emphysema. We have established an experimental model of lung emphysema by the administration of protease (Couillin I in preparation). Emphysema is induced within 2 weeks and several therapeutic approaches are being tested.
- IL17 Asthma
- Inflammasome asthma
- ILC3-derived acetylcholine promotes protease-driven allergic lung pathology
- Fibrosis: from mechanisms to medicines
- Cytokine Storm
Corona virus and Influenza may lead to acute severe pneumonia which may be fatal. Especially the emergence of the COVID-19 strain and new influenza strains such as H1N1 represents an important public health concern.
We have established a lung infection model with COVID-19 and H1N1 strain infection which causes severe lung inflammation within a few days which may lead to death of infected in hu K18ACE2 mice and Syrian hamsters. These model serve to test novel therapeutics, which inhibit exuberant lung inflammation. Novel antiviral compounds and vaccines may be tested in this model. Furthermore, we have established Rhinovirus and RSV infection.
- SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function
- Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
Recent insights revealed that the microbiota of our body plays an important part in homeostasis and diseases.
IL-1b in P. aeruginosa Pneumonia
We have established murine models of human skin disease such as psoriasis, atopic dermatitis and wound healing
- Pathogenesis of fibrosis in interstitial lung disease
- Osteoarthritis year 2010 in review: pathomechanisms
Study protocols are established.